XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash $ 401,803 $ 3,165,985
Prepaid expenses and other current assets 764,964 1,366,704
Current assets of discontinued operations 6,287,849
Total current assets 1,166,767 10,820,538
Property and equipment, net 26,242
Other assets 866,481
Non-current assets of discontinued operations 8,236,711
Total Assets 2,033,248 19,083,491
Current liabilities    
Accounts payable 2,222,983 619,568
Accrued expenses and other current liabilities 560,006 864,559
Warrant liabilities 54,600 788,100
Warrant liabilities - related party 2,834,547
Convertible debt - related party 1,299,216 60,197
Current liabilities of discontinued operations 3,441,198
Total current liabilities 4,136,805 8,608,169
Non-current liabilities of discontinued operations 1,708,732
Total liabilities 4,136,805 10,316,901
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):    
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively 43,262 42,110
Additional paid-in capital 114,655,565 110,528,050
Accumulated other comprehensive income 50,721
Accumulated deficit (116,802,384) (103,385,172)
Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit) (2,103,557) 7,235,709
Noncontrolling interest 1,530,881
Total Stockholders’ Equity (deficit) (2,103,557) 8,766,590
Total Liabilities & Stockholders’ Equity (Deficit) $ 2,033,248 $ 19,083,491